<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295278</url>
  </required_header>
  <id_info>
    <org_study_id>PDXN-BP-001</org_study_id>
    <nct_id>NCT04295278</nct_id>
  </id_info>
  <brief_title>Feasibility Study of MicroKine Dx System in Critically-ill Pediatric Patients.</brief_title>
  <official_title>An Observational Phase 0 Study to Assess the Performance and Real-world Feasibility of Implementing the MicroKine Dx Biomarker-based Risk Stratification of Critically-ill Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PreDxion Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PreDxion Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll approximately 25 pediatric patients to assess the performance and
      real-world feasibility of multi-biomarker based prognostic and predictive algorithms to aid
      in the clinical management of pediatric critically-ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 25 pediatric patients to assess the predictive
      performance of multi-biomarker based prognostic and predictive algorithms to aid in the
      clinical management of pediatric critically-ill patients.

      All enrolled patients will undergo a series of blood collection procedures during their
      admission to the pediatric intensive care unit. The levels of inflammatory cytokines,
      chemokines, and effectors will be assessed and used in multi-biomarker based prognostic and
      predictive algorithms to determine patients at risk of in-hospital mortality.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
    <description>28-day in hospital mortality</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Organ Failure</condition>
  <arm_group>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
    <description>Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MicroKine Dx system</intervention_name>
    <description>Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.</description>
    <arm_group_label>Systemic inflammatory response syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric critically-ill patients 38-weeks gestation to 21 years of age admitted to a
        pediatric intensive care unit within the last 24-hours, with &gt;1 indwelling central
        catheter, and meeting ≥2 age-adapted SIRS criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age 38 weeks gestation to 21 years of age

          2. Admitted to the PICU within the prior 24 hours

          3. Indwelling catheters for obtaining blood

          4. Meet ≥2 age-adapted SIRS criteria

        Key Exclusion Criteria:

          1. Anticipated pediatric intensive care unit admission &lt;24 hours

          2. Primary immunodeficiency

          3. Limited resuscitation, no escalation of treatment, do not resuscitate, or other
             limitations to care

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>38 Weeks</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Information</last_name>
    <role>Study Director</role>
    <affiliation>PreDxion Bio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Information</last_name>
    <phone>(650) 877-2309‬</phone>
    <email>clinicaltrials@predxionbio.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

